Literature DB >> 23532395

Personalized therapy in gynecological cancer: a reality in clinical practice?

Susana Banerjee1, Martin Gore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23532395     DOI： 10.1007/s11912-013-0314-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  10 in total

1.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

Authors:  Filip Janku; Jennifer J Wheler; Shannon N Westin; Stacy L Moulder; Aung Naing; Apostolia M Tsimberidou; Siqing Fu; Gerald S Falchook; David S Hong; Ignacio Garrido-Laguna; Rajyalakshmi Luthra; J Jack Lee; Karen H Lu; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

2.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

3.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Carol Aghajanian; Stephanie V Blank; Barbara A Goff; Patricia L Judson; Michael G Teneriello; Amreen Husain; Mika A Sovak; Jing Yi; Lawrence R Nycum
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

5.  Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.

Authors:  John Farley; William E Brady; Vinod Vathipadiekal; Heather A Lankes; Robert Coleman; Mark A Morgan; Robert Mannel; S Diane Yamada; David Mutch; William H Rodgers; Michael Birrer; David M Gershenson
Journal:  Lancet Oncol       Date:  2012-12-21       Impact factor: 41.316

Review 6.  New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.

Authors:  Susana Banerjee; Stanley B Kaye
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

Review 7.  Molecular targets and targeted therapeutics in endometrial cancer.

Authors:  Britta Weigelt; Susana Banerjee
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

8.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

Authors:  Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Euan Macpherson; Claire Watkins; James Carmichael; Ursula Matulonis
Journal:  N Engl J Med       Date:  2012-03-27       Impact factor: 91.245

Review 9.  Making the best of PARP inhibitors in ovarian cancer.

Authors:  Susana Banerjee; Stan B Kaye; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-08-10       Impact factor: 66.675

10.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.